This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Clovis (CLVS) Down 12.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXH
Gilead (GILD) Announces Positive New Data on Breast Cancer Drug
by Zacks Equity Research
Gilead (GILD) breast cancer drug Trodelvy shows efficacy across HER2-low and IHC0 status in pre-treated metastatic breast cancer patients.
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $63.82, marking a -1.74% move from the previous day.
Horizon Therapeutics (HZNP) Down 9.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Gilead (GILD) Up 1.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
by Zacks Equity Research
Sector ETF report for FXH
Jounce (JNCE) SELECT Study Fails to Meet Goal, Stock Down
by Zacks Equity Research
Jounce Therapeutics (JNCE) declines as its mid-stage study, SELECT, evaluating vopratelimab in lung cancer patients, fails to meet the primary endpoint.
Gilead (GILD) Outpaces Industry in Six Months: What Lies Ahead?
by Zacks Equity Research
Gilead (GILD) gains on the back of its strong HIV franchise and promising oncology business, which should propel growth further.
Is Franklin U.S. Low Volatility High Dividend Index ETF (LVHD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for LVHD
Biotech Stock Roundup: GILD, BLUE, AXSM's Drug Approvals, FHTX Study Update & More
by Zacks Equity Research
Regulatory updates from Gilead (GILD) and Axsome (AXSM) are a few key highlights from the biotech sector during the past week.
Should Invesco S&P Ultra Dividend Revenue ETF (RDIV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RDIV
Gilead (GILD) Twice-Yearly HIV Treatment Gets EC Approval
by Zacks Equity Research
Gilead (GILD) HIV treatment Sunlenca gets approved by the European Commission for adults with multi-drug resistant HIV infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.
How Are Biotech ETFs Reacting to Q2 Earnings Releases?
by Sanghamitra Saha
he Biotech sector has been in a sweet spot for quite some time now. Plus, earnings releases have also come in mostly upbeat.
Biotech Stock Roundup: GILD's Drug News, NVAX & MRNA COVID-19 Vaccine Updates
by Zacks Equity Research
Regulatory and pipeline updates from Gilead (GILD) and Moderna (MRNA) are a few key highlights from the biotech sector during the past week.
Gilead (GILD) Announces Positive Data on Breast Cancer Drug
by Zacks Equity Research
Gilead (GILD) breast cancer drug Trodelvy improves overall survival in pre-treated HR+/HER2- metastatic breast cancer patients. The company will also acquire the remaining rights to the drug.
Is VanEck Morningstar Wide Moat ETF (MOAT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for MOAT
Gilead (GILD) Q2 Earnings & Sales Top, Revenue Outlook Upped
by Zacks Equity Research
Gilead (GILD) reports better-than-expected second quarter results on strong HIV business. The company also raises its annual revenue guidance.
Should VanEck Morningstar Wide Moat ETF (MOAT) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for MOAT
Gilead Sciences (GILD) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of 4.64% and 6.55%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Is a Beat in Store for BioNTech (BNTX) This Earnings Season?
by Zacks Equity Research
On BioNTech's (BNTX) second-quarter earnings call, investors are expected to focus on the sales performance of its COVID-19 vaccine, Comirnaty, developed in partnership with Pfizer.
Drug, Biotech Stocks' Q2 Earnings on Aug 2: GILD, INCY & More
by Zacks Equity Research
Let's check out how the four pharma/drug/biotech companies are placed before the quarterly earnings release on Aug 2.
Viatris (VTRS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on top-line and bottom-line numbers when Viatris (VTRS) reports second-quarter results.
Exelixis (EXEL) to Post Q2 Earnings: What is in the Cards?
by Zacks Equity Research
Investors will likely focus on the demand for Cabometyx and pipeline updates when Exelixis (EXEL) reports Q2 results. Operating expenses might have jumped.
Novo Nordisk (NVO) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Novo Nordisk's (NVO) top line is likely to have been driven by sales of its Diabetes and Obesity Care products in the second quarter of 2022.